ClinicalTrials.gg
CompletedNCT05097014TRIFORCEUpdated Mar 24, 2023

CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD

A Phase 4 interventional study of CHF5993 and CHF1535 in Chronic Obstructive Pulmonary Disease, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Germany. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2023-03-24.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Chiesi Farmaceutici S.p.A..

Enrollment
25th of 59
106 · median 65
Started
2021
with 6 others
Phase 4
3 of 68
none open now
Registered
56th of 68
by date

Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., this one is the 25th largest by enrollment of the 59 interventional ones that give a count, is one of 7 that started in 2021, is one of 3 in phase 4, and was the 56th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

5 of the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

Double Blind, Multinational, Multicentre, Randomised, Placebo-Controlled, 3-Way Cross-Over Study To Evaluate The Effect Of A Triple Combination Of Beclometasone Dipropionate And Formoterol Fumarate Plus Glycopyrronium (CHF5993) And A Dual Combination Of Beclometasone Dipropionate Plus Formoterol Fumarate (CHF1535) Both Administered Via pMDI On Lung Hyperinflation And Exercise Endurance Time In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Lung hyperinflation, exercise endurance time
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A signed and dated written obtained prior to any study-related procedures.
  2. Outpatient population.
  3. Male or female subjects.
  4. diagnosis for at least 12 months before the Screening visit in accordance with the definition by the GOLD 2020 report.
  5. Current or ex-smokers (who quit smoking for at least 6 months prior to Screening Visit) with a smoking history of at least 10 pack-years [pack-years = (number of cigarettes per day x number of years)/20]. E-cigarettes smoking cannot be used to calculate pack-year history.
  6. A post-bronchodilator /FVC \< 0.7 within 30 min after 4 puffs (4 x 100 µg) of salbutamol pMDI and a post-bronchodilator FEV1 ≥ 40% and \<80% of the predicted normal values. If this is not met at screening, the test can be repeated once before randomisation.
  7. Pre-bronchodilator functional residual capacity (FRC) of > 120% of predicted normal FRC values at Screening visit 1. If this criterion is not met at screening, the test can be repeated once before randomisation.
  8. A score of >2 on the Modified Medical Research Council Dyspnea Scale (mMRC) at Visit 1.
  9. Subjects on mono- or dual inhaled maintenance COPD treatment at a stable dose for at least 3 months prior to screening.
  10. A cooperative attitude and ability to correctly use the study inhalers.
  11. Female subjects must be women either of non- (WONCBP) defined as physiologically incapable of becoming pregnant (i.e. or permanently sterile) or physiologically capable of becoming pregnant (i.e. women of childbearing potential (WOCBP)).

    Inclusion criteria assessed prior to Randomization:

  12. CWRCE at Visit 1b: between 2 min and 11 min at 80% of maximum workload. In case the subject cycles for a shorter (i.e. \< 2 min) or longer (i.e. > 11 min) period, the visit can be repeated with an adjusted workload once within a 1-week period.
  13. Oxygen saturation (SpO2 measured by pulse oximeter) at least 82% during the incremental exercise test (IET) performed in the run-in period.
  14. Subjects must be able to complete CWRCE at Visit 1b and then at Visit 2 without requirement for supplemental oxygen.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women.
  2. Known respiratory disorders other than which may impact the efficacy of the study drug according the investigator's judgment. This can include but is not limited to current diagnosis of asthma, alfa-1 antitrypsin deficiency, active tuberculosis, lung cancer, severe bronchiectasis unrelated to COPD, sarcoidosis, lung fibrosis, pulmonary hypertension and interstitial lung disease.
  3. Unstable concurrent disease: e.g. fever, uncontrolled hyperthyroidism, uncontrolled diabetes mellitus or other endocrine disease; significant hepatic impairment; significant renal impairment; uncontrolled gastrointestinal disease (e.g. active peptic ulcer); uncontrolled cardiac disease, uncontrolled neurological disease; uncontrolled haematological disease; uncontrolled disorders, or other which may impact the efficacy or the safety of the study drug according to investigator's judgment.
  4. Moderate (requiring prescriptions of systemic and/or antibiotics) or severe (leading to hospitalization) COPD exacerbation in the 3 and 12 months, respectively, prior to Screening visit 1 and during the run-in period.
  1. Subjects requiring long term (> 15 hours a day) oxygen therapy for chronic hypoxemia.
  1. Subjects who have clinically severe cardiovascular condition (such as but not limited to unstable ischemic heart disease, Class IV, left ventricular failure, myocardial infarction in the prior 6 months, not controlled arrhythmia etc.), which may impact the efficacy or the safety of the study drug according to the investigator's judgement.
  1. An abnormal and 12-lead (ECG) which may impact the safety of the subject according to investigator's judgement. Subjects whose 12-lead ECG shows >450 ms for males or QTcF >470 ms for females at screening visit are not eligible.
  1. History of to M3 receptor antagonists, β2-agonist, corticosteroids or any of the contained in any of the formulations used in the trial which may raise or impact the efficacy of the study drug according to the investigator's judgement.
  1. Subjects with serum potassium levels ≤ 3.5 mEq/L (or 3.5 mmol/L) 9. Subjects with less than 15 or greater than 35 kg/m2. 10. History of alcohol abuse and/or substance/drug abuse within 12 months prior to screening visit.
  1. Subjects with contraindications to cardiopulmonary exercise testing, including those whose exercise test is limited by non-respiratory or cardiovascular condition, e.g. by neurologic, orthopaedic, or other disorders.
  1. Participation in another clinical trial where drug was received less than 30 days or 5 half-lives whichever is longer prior to screening visit.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
106 participants (actual)

Study arms

  • Active comparator
    CHF5993

    pMDI fixed combination product of beclometasone dipropionate (BDP) 100 µg plus 6 µg of formoterol fumarate (FF) and 10 µg of glycopyrronium (G)

    Drug: CHF5993

  • Active comparator
    CHF1535

    pMDI fixed combination product beclometasone dipropionate (BDP) 100 µg plus 6 µg of formoterol fumarate (FF)

    Drug: CHF1535

  • Placebo comparator
    Matched placebo

    Matched placebo pMDI

    Other: Matched placebo

Interventions

  • Pressurized metered dose inhaler (pMDI) 2 inhalations bid

    Also known as: TRIMBOW®

  • Pressurized metered dose inhaler (pMDI) 2 inhalations bid

    Also known as: FOSTER®

  • OtherMatched placebo

    Pressurized metered dose inhaler (pMDI) 2 inhalations bid

06

What researchers measure

Primary outcomes

  1. Inspiratory capacity (IC) prior to Constant Work Rate Cycle Ergometry (CWRCE) test

    Change from baseline in 2-hour post-dose

    Time frame: 3 weeks of treatment

Secondary outcomes

  1. IC at Isotime, defined as the shortest CWRCE test duration among baseline and end of treatment period.

    Change from baseline

    Time frame: 3 weeks of treatment

  2. Exercise endurance time (EET)

    Change from baseline in 2-hour post-dose

    Time frame: 3 weeks of treatment

Other outcomes

  1. EET between CHF5993 and CHF1535

    Change from baseline in 2-hour post-dose

    Time frame: 3 weeks of treatment

  2. Pre-dose morning Forced Expiratory Volume in 1 second (FEV1)

    Change from baseline

    Time frame: 3 weeks of treatment

  3. Pre-dose Forced Vital Capacity (FVC)

    Change from baseline

    Time frame: 3 weeks of treatment

  4. Functional Residual Capacity (FRC)

    Change from baseline in 2-hour post-dose

    Time frame: 3 weeks of treatment

  5. Pre-dose IC

    Change from baseline

    Time frame: 3 weeks of treatment

  6. Residual Volume (RV)

    Change from baseline in 2-hour post-dose

    Time frame: 3 weeks of treatment

  7. RV/Total Lung Capacitity (TLC) ratio

    Change from baseline in 2-hour post-dose

    Time frame: 3 weeks of treatment

  8. Dyspnoea intensity at isotime (using the modified Borg scale)

    Change from baseline

    Time frame: 3 weeks of treatment

  9. Physical activity (steps/day)

    Change from baseline

    Time frame: 3 weeks of treatment

07

Study locations

1 site
  • PAREXEL International GmbH Early Phase Clinical Unit Berlin
    Berlin-Spandau, Berlin Spandauer Damm 130 D-14050, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information. Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Access criteria: Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.

Data sharing details ↗ · www.chiesi.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Feb 2023, 15 months.

Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 15 months is close to that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2021
First posted
Oct 27, 2021
StartActual
Oct 28, 2021
Primary completionActual
Feb 24, 2023
CompletionActual
Feb 24, 2023
Last update
Mar 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05097014
Responsible party
Sponsor
First posted
Oct 27, 2021
Start date
Oct 28, 2021
Primary completion
Feb 24, 2023
Completion
Feb 24, 2023
Last update
Mar 24, 2023

Study contacts

Henrik Watz, MD
study director · Pulmonary Research Institute at LungenClinic Grosshansdorf, German Center for Lung Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CHF5993 · CHF 1535

Start the discussion